SCHEMBL5486990

SCHEMBL5486990

N#Cc1cccc(C=CC(=O)N2CCN(c3ncccc3C#N)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
ENPP2 Q13822 1/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
RECQL P46063 1/20 0.47
PANK3 Q9H999 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
HDAC2 Q92769 2/20 0.45
APP P05067 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
GRM5 P41594 1/20 0.44
PARP1 P09874 2/20 0.43
PARP2 Q9UGN5 1/20 0.43
PARP3 Q9Y6F1 1/20 0.43
SLC6A7 Q99884 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5486984 1.00 L3MBTL1 (0.53) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5481413 0.89 LMNA (0.52) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5486556 0.89 L3MBTL1 (0.69) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5480813 0.89 KDM4E (0.55) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5475934 0.89 ENPP2 (0.59) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5475932 0.89 ENPP2 (0.59) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5481406 0.89 LMNA (0.52) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5480821 0.89 KDM4E (0.55) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5486563 0.89 L3MBTL1 (0.69) L3MBTL1ENPP2KDM4EALDH1A1TDP1
SCHEMBL5484924 0.87 L3MBTL1 (0.51) L3MBTL1KDM4EALDH1A1APPGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US claimed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists GRM5, GRM1, GRM3 L3MBTL1 4137/4885ENPP2 2635/4885KDM4E 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.